Home Tags Elahere®
The MIRASOL study (ClinicalTrials.gov identifier: NCT04209855), an international phase 3 randomized clinical trial, found that mirvetuximab soravtansine (Elahere™, ImmunoGen), an antibody-drug conjugate (ADC) and microtubule inhibitor, significantly improved progression-free and overall survival for women with platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha (FRɑ) expression.
On November 14, 2022 the US Food and Drug Administration (FDA) granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere®; ImmunoGen), for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who had received one to three prior systemic treatment regimens.
Mirvetuximab Soravtansine Demonstrates Overall Survival Benefit in FRα-Positive Platinum-Resistant Ovarian Cancer
Positive top-line data from the Phase 3 confirmatory MIRASOL trial (NCT04209855; GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of mirvetuximab soravtansine-gynx compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy.
With renewed focus and commitment in creating a platform for innovative scientific insights and transformative experiences, 13th World ADC in London, held March 13...
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere®; ImmunoGen), previously known as IMGN853, for the treatment of patients diagnosed...